146 related articles for article (PubMed ID: 11470995)
1. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2.
Han XM; Ou-Yang DS; Lu PX; Jiang CH; Shu Y; Chen XP; Tan ZR; Zhou HH
Pharmacogenetics; 2001 Jul; 11(5):429-35. PubMed ID: 11470995
[TBL] [Abstract][Full Text] [Related]
2. G-2964A and C734A genetic polymorphisms of CYP1A2 in Chinese population.
Han XM; Chen XP; Wu QN; Jiang CH; Zhou HH
Acta Pharmacol Sin; 2000 Nov; 21(11):1031-4. PubMed ID: 11501059
[TBL] [Abstract][Full Text] [Related]
3. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.
Gunes A; Ozbey G; Vural EH; Uluoglu C; Scordo MG; Zengil H; Dahl ML
Pharmacogenomics; 2009 May; 10(5):769-78. PubMed ID: 19450128
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.
Ghotbi R; Christensen M; Roh HK; Ingelman-Sundberg M; Aklillu E; Bertilsson L
Eur J Clin Pharmacol; 2007 Jun; 63(6):537-46. PubMed ID: 17370067
[TBL] [Abstract][Full Text] [Related]
5. Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine.
Sachse C; Brockmöller J; Bauer S; Roots I
Br J Clin Pharmacol; 1999 Apr; 47(4):445-9. PubMed ID: 10233211
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
Carrillo JA; Christensen M; Ramos SI; Alm C; Dahl ML; Benitez J; Bertilsson L
Ther Drug Monit; 2000 Aug; 22(4):409-17. PubMed ID: 10942180
[TBL] [Abstract][Full Text] [Related]
7. Breast Cancer Association with CYP1A2 Activity and Gene Polymorphisms--a Preliminary Case-control Study in Tunisia.
Imene A; Maurice AJ; Arij M; Sofia P; Saad S
Asian Pac J Cancer Prev; 2015; 16(8):3559-63. PubMed ID: 25921178
[TBL] [Abstract][Full Text] [Related]
8. Association between common CYP1A2 polymorphisms and theophylline metabolism in non-smoking healthy volunteers.
Wang L; Hu Z; Deng X; Wang Y; Zhang Z; Cheng ZN
Basic Clin Pharmacol Toxicol; 2013 Apr; 112(4):257-63. PubMed ID: 23167834
[TBL] [Abstract][Full Text] [Related]
9. Correlation between assessment of cytochrome P450 1A2 activity and enzyme activity scores, and their relation to clozapine exposure.
Alarcan H; Cannet P; Camus V; Fond G; Zendjidjian X; Guilhaumou R; Quaranta S
Br J Clin Pharmacol; 2023 May; 89(5):1665-1671. PubMed ID: 36507652
[TBL] [Abstract][Full Text] [Related]
10. The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population.
Chen X; Wang L; Zhi L; Zhou G; Wang H; Zhang X; Hao B; Zhu Y; Cheng Z; He F
Clin Pharmacol Ther; 2005 Sep; 78(3):249-59. PubMed ID: 16153396
[TBL] [Abstract][Full Text] [Related]
11. The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects.
Welfare MR; Bassendine MF; Daly AK
Br J Clin Pharmacol; 2000 Mar; 49(3):240-3. PubMed ID: 10718779
[TBL] [Abstract][Full Text] [Related]
12. Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians.
Welfare MR; Aitkin M; Bassendine MF; Daly AK
Pharmacogenetics; 1999 Jun; 9(3):367-75. PubMed ID: 10471069
[TBL] [Abstract][Full Text] [Related]
13. Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers.
Muscat JE; Pittman B; Kleinman W; Lazarus P; Stellman SD; Richie JP
Biochem Pharmacol; 2008 Oct; 76(7):929-37. PubMed ID: 18703023
[TBL] [Abstract][Full Text] [Related]
14. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2.
Han XM; Ouyang DS; Chen XP; Shu Y; Jiang CH; Tan ZR; Zhou HH
Br J Clin Pharmacol; 2002 Nov; 54(5):540-3. PubMed ID: 12445035
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.
Sachse C; Bhambra U; Smith G; Lightfoot TJ; Barrett JH; Scollay J; Garner RC; Boobis AR; Wolf CR; Gooderham NJ;
Br J Clin Pharmacol; 2003 Jan; 55(1):68-76. PubMed ID: 12534642
[TBL] [Abstract][Full Text] [Related]
16. Influence of the genetic polymorphism in the 5'-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers.
Pavanello S; Pulliero A; Lupi S; Gregorio P; Clonfero E
Mutat Res; 2005 Nov; 587(1-2):59-66. PubMed ID: 16188490
[TBL] [Abstract][Full Text] [Related]
17. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
[TBL] [Abstract][Full Text] [Related]
18. Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking.
Dobrinas M; Cornuz J; Pedrido L; Eap CB
Pharmacogenet Genomics; 2012 Feb; 22(2):143-51. PubMed ID: 22246422
[TBL] [Abstract][Full Text] [Related]
19. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes.
Djordjevic N; Ghotbi R; Bertilsson L; Jankovic S; Aklillu E
Eur J Clin Pharmacol; 2008 Apr; 64(4):381-5. PubMed ID: 18157525
[TBL] [Abstract][Full Text] [Related]
20. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
Butler MA; Lang NP; Young JF; Caporaso NE; Vineis P; Hayes RB; Teitel CH; Massengill JP; Lawsen MF; Kadlubar FF
Pharmacogenetics; 1992 Jun; 2(3):116-27. PubMed ID: 1306111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
